«Seqens has invested heavily to create a strong pharmaceutical business»
Pierre Luzeau was interviewed by Sylvie Latieule for Info chimie magazin (issue 553) realesed on February. Discover more about the group history, its aspirations and why it became Seqens.
Pierre Luzeau was interviewed by Sylvie Latieule for Info chimie magazine (issue 553) released on February. Discover more about the group history, our aspirations and why we became Seqens.
a new name to reflect the group expansion
After 15 years of practically uninterrupted external growth, Novacap group changed its name for Seqens. Pierre Luzeau, Seqens CEO, reviews the group achievements and talks about its aspirations. Seqens which now shares its offers between two activities – pharmaceutical synthesis and Specialty Ingredients – has exceeded the turnover of half a billion euros.
We made the choice to focus on two preferential markets: pharmaceuticals and specialty ingredients destined for high value markets, such as cosmetics, electronics and environmental services…